CTOs on the Move

Chambrel At Williamsburg

www.chambrel.com

 
Chambrel At Williamsburg is a Williamsburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.chambrel.com
  • 3800 Treyburn Dr
    Williamsburg, VA USA 23185
  • Phone: 757.220.1839

Executives

Name Title Contact Details

Similar Companies

CareAllies

CareAllies works side-by-side with health care providers to help improve the quality, value and experience of care for their patients, to make health care better for everyone. Our aim: To support doctor-patient-community engagement that enhances the quality and affordability of care. It`s how physicians and health systems will deliver sustainable value-based care and continue to thrive in the future.

Flashpoint-Diccicco Battista Communications

Flashpoint-Diccicco Battista Communications is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Institute For Diabetes Dscvry

Institute For Diabetes Dscvry is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Buoy Health

Buoy is a Boston-based digital health company that uses AI technology to provide personalized clinical support the moment an individual has a health concern. Developed out of the Harvard Innovation Labs by a team of doctors and data scientists, Buoy navigates people through the healthcare system intelligently, delivering triage at scale, and connecting them with the right care endpoints at the right time based on self-reported symptoms.

ForSight VISION5

ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.